Biotech & Medtech
Biotech & Medtech news — Sunday 27 September 2026
4 stories from 1 sources, every one in English. Each links to its publisher.
-
Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder
MedCity News
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum…
-
When AI Gets Medicine Wrong, Who’s Liable?
MedCity News
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported…
-
Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need
MedCity News
As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to…
-
MedTech Commercialization Gap: Moving Beyond Technical Viability
MedCity News
What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem. The post MedTech…